Marike Gabrielson
About me
Associate professor (docent) in molecular cancer epidemiology at Karolinska Institutet at the Department of Medical Epidemiology and Biostatistics. My research focuses on the aetiology of breast cancer with an emphasis on the molecular epidemiology of breast cancer risk and prevention, and precision medicine.
My research is supported by grants from The Swedish Cancer Society, The Sjöberg foundation (Sjöbergstiftelsen), Radiumhemmets Forskningsfonder, Region Stockholm with KTH, and Karolinska Institutet’s Research grants. The POWER trial is additionally supported by grants from Bröstcancerförbundet.I am co-director of BRECT – the Karolinska Institutet’s Breast Cancer Theme Centre.
I am co-director om MEB-WISE – the organisation for Women in Science at the department of Medical Epidemiology and Biostatistics.
Research
My research focuses on deciphering molecular and epidemiological mechanisms that drive treatment adherence, treatment efficacy, and risk of breast cancer. My overarching research goal is to individualise adjuvant care and primary prevention of breast cancer. I conduct research within three target areas:
1) Sponsor and chief scientific officer of the POWER trial on individualised adjuvant tamoxifen for breast cancer patients; a new clinical trial in precision medicine of breast cancer
2) Understanding the mechanisms of action of the drug tamoxifen in preventing breast cancer, and identifying biomarkers for tailoring individualised preventive and adjuvant therapy
3) Deciphering the biology of breast cancer risk, and identifying biomarkers of risk within the breast and tissue and by hormone and proteomic profiles
Articles
- Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025;117(4):629-636
- Article: BMC HEALTH SERVICES RESEARCH. 2025;25(1):344
- Article: BREAST CANCER RESEARCH. 2024;26(1):163
- Article: INTERNATIONAL JOURNAL OF CANCER. 2024;155(2):339-351
- Article: BRITISH JOURNAL OF CANCER. 2024;130(4):620-627
- Article: JOURNAL OF MEDICAL GENETICS. 2023;60(12):1186-1197
- Article: NATURE COMMUNICATIONS. 2023;14(1):7680
- Article: BREAST CANCER RESEARCH. 2023;25(1):93
- Article: CANCER MEDICINE. 2023;12(15):16142-16162
- Article: BRITISH JOURNAL OF CANCER. 2023;129(1):61-71
- Article: CANCERS. 2023;15(13):3313
- Article: INTERNATIONAL JOURNAL OF CANCER. 2023;152(11):2362-2372
- Article: EUROPEAN JOURNAL OF HUMAN GENETICS. 2023;31(5):578-587
- Journal article: EUROPEAN JOURNAL OF HUMAN GENETICS. 2023;31(5):578-587
- Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2022;114(12):1706-1719
- Article: BRITISH JOURNAL OF SPORTS MEDICINE. 2022;56(20):1157-1170
- Article: EUROPEAN JOURNAL OF CANCER. 2022;173:178-193
- Article: ONCOLOGIST. 2022;27(7):e597-e600
- Article: ONCOLOGIST. 2022;27(7):e601-e603
- Article: GENOME MEDICINE. 2022;14(1):51
- Article: SCIENTIFIC REPORTS. 2022;12(1):6199
- Article: TRANSLATIONAL ONCOLOGY. 2022;17:101339
- Article: JAMA ONCOLOGY. 2022;8(3):e216744
- Article: COMMUNICATIONS BIOLOGY. 2022;5(1):65
- Article: ANNALS OF ONCOLOGY. 2021;32(10):1286-1293
- Article: BRITISH JOURNAL OF CANCER. 2021;125(5):759-765
- Article: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(17):1899-1908
- Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2021;113(3):329-337
- Article: INTERNATIONAL JOURNAL OF CANCER. 2021;148(5):1132-1143
- Article: NEW ENGLAND JOURNAL OF MEDICINE. 2021;384(5):428-439
- Article: MOLECULAR AND CLINICAL ONCOLOGY. 2021;14(2):42
- Journal article: EUROPEAN JOURNAL OF CANCER. 2020;138:s13
- Article: BREAST CANCER RESEARCH. 2020;22(1):95
- Article: GENETIC EPIDEMIOLOGY. 2020;44(5):442-468
- Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2020;112(4):391-399
- Article: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2020;29(3):574-581
- Article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2020;49(1):216-232
- Article: NATURE GENETICS. 2020;52(1):56-73
- Article: NPJ BREAST CANCER. 2019;5:38
- Article: NATURE COMMUNICATIONS. 2019;10(1):4648
- Article: SCIENTIFIC REPORTS. 2019;9(1):12524
- Article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2019;48(3):795-806
- Journal article: ANNALS OF ONCOLOGY. 2019;30:iii4-iii5
- Article: NATURE COMMUNICATIONS. 2019;10(1):1741
- Article: BRITISH JOURNAL OF CANCER. 2019;120(6):647-657
- Article: JNCI CANCER SPECTRUM. 2019;3(1):pkz004
- Article: AMERICAN JOURNAL OF HUMAN GENETICS. 2019;104(1):21-34
- Article: JNCI CANCER SPECTRUM. 2018;2(4):pky055
- Article: BREAST CANCER RESEARCH AND TREATMENT. 2018;170(3):487-497
- Article: NATURE GENETICS. 2018;50(7):968-978
- Article: HUMAN MUTATION. 2018;39(5):729-741
- Article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2018;47(2):526-536
- Article: BREAST CANCER RESEARCH. 2018;20(1):14
- Article: NATURE GENETICS. 2017;49(12):1767-1778
- Article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2017;46(6):1740-1741g
- Article: ONCOTARGET. 2017;8(61):102769-102782
- Article: NATURE. 2017;551(7678):92-94
- Article: NATURE GENETICS. 2017;49(6):834-841
- Article: BREAST CANCER RESEARCH AND TREATMENT. 2016;158(2):253-261
- Article: NATURE COMMUNICATIONS. 2016;7:11375
- Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2016;469(4):1090-1096
- Article: JOURNAL OF VASCULAR RESEARCH. 2016;53(1-2):17-26
- Article: PLOS ONE. 2014;9(9):e107109
- Article: ONCOLOGY REPORTS. 2013;29(4):1268-1274
- Article: BMC CANCER. 2012;12:350
- Article: PLOS ONE. 2011;6(2):e16798
- Show more
All other publications
- Preprint: RESEARCH SQUARE. 2024
- Preprint: RESEARCH SQUARE. 2023
- Preprint: MEDRXIV. 2021
- Preprint: RESEARCH SQUARE. 2021
- Preprint: RESEARCH SQUARE. 2021
- Preprint: RESEARCH SQUARE. 2021
- Preprint: BIORXIV. 2021
- Conference publication: EUROPEAN JOURNAL OF CANCER. 2020;138:S13
- Conference publication: ANNALS OF ONCOLOGY. 2019;30:4-5
- Preprint: BIORXIV. 2019
- Conference publication: CLINICAL CANCER RESEARCH. 2013;19:a36
Grants
- Compliance and response to tamoxifen therapy in breast cancer – A project in precision medicine and individualised therapySwedish Cancer Society1 January 2025 - 31 December 2027
- Swedish Cancer Society1 January 2025 - 31 December 2029
- Sjöbergstiftelsen1 January 2025 - 31 December 2027
- The POWER trial: A randomised open label phase 3 clinical trial on Personalised dose Optimisation With adjuvant tamoxifen therapy in breast cancERRadium Hemmets Research Funds1 January 2025 - 31 December 2026
- Swedish Cancer Society1 July 2024 - 30 June 2030
- Biological markers for prediction of therapy response by tamoxifenCancerfonden1 January 2022 - 31 December 2024
- Individualised primary prevention of breast cancer with tamoxifen in high-risk individualsCancerfonden1 January 2022 - 31 December 2024
- The biology of breast cancer risk and prevention with tamoxifenKarolinska Institutet1 January 2021
- The biological mechanisms of mammography density as a risk factor for breast cancerKarolinska Institutet1 January 2019
Employments
- Principal Researcher, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2025-
- Senior Research Specialist, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2018-2025
Degrees and Education
- Docent, Karolinska Institutet, 2023
Supervision
- Nida Khan, Breast reconstruction: a critical analysis of modern strategies, their associated economic burden and patient-reported outcomes, 2024-
- Mattias Hammarström, Investigating the outcome of low and standard dose tamoxifen in healthy women, 2021-
- Shadi Azam, Determinants and influence of mammographic features on breast cancer risk, 2020